Vice President, Marketing

USA (Remote)

$320K/yr – $350K/yrSenior Level15+ years expFull time

Posted 2 hrs ago

Job Summary

Own the CAR-T portfolio commercial strategy across autoimmune indications, lead the launch and lifecycle plans, and partner across Medical Affairs, Market Access, Regulatory, Sales, and Clinical Development to drive adoption and value realization.

  • Own the CAR-T portfolio commercial strategy across indications
  • Shape launch plans, lifecycle strategy, and cross-functional engagement
  • Collaborate with Medical Affairs, Market Access, Regulatory, and Sales to drive adoption

Job Description

Responsibilities

  • Own the commercial marketing strategy for the company’s CAR-T portfolio across current and future autoimmune indications
  • Develop and lead the overall marketing strategy and commercial vision, establishing the strategic foundation, capabilities, infrastructure, and organizational readiness
  • Define launch objectives, customer priorities, brand positioning, messaging, channel strategy, unbranded education, promotional approach, and measurement
  • Translate clinical data, market research, competitive intelligence, and customer insights into actionable marketing strategies
  • Develop a deep understanding of the patient journey, referral ecosystem, treatment pathways, and barriers to adoption across autoimmune diseases
  • Lead the marketing organization through the company’s first product launch and establish a repeatable launch model for subsequent indications, expansion and products
  • Establish launch performance metrics and continuously evaluate market feedback, customer behavior, competitive activity, and emerging data to optimize strategy
  • Develop post-launch strategies that accelerate adoption, strengthen customer relationships, and maximize the value of each indication
  • Establish differentiated strategies as the product expands into additional patient populations or disease settings
  • Partner with Clinical Development and Medical Affairs to incorporate emerging clinical data and external insights into lifecycle planning

Requirements

  • 15+ years of progressive experience in biopharmaceutical commercial/marketing roles, with significant experience in specialty, rare disease, hematology, immunology, or other complex therapeutic markets
  • Demonstrated experience personally leading at a successful U.S. product launch from pre-launch through commercialization
  • Experience developing commercialization strategies for innovative therapies, preferably CAR-T, cell therapy, gene therapy, or other highly specialized treatments
  • Proven experience developing multi-indication and lifecycle strategies for a pharmaceutical or biotechnology asset
  • Experience building or significantly transforming a marketing organization in a growth-stage or emerging biotech environment
  • Strong understanding of commercialization, brand strategy, market development, customer segmentation, personal and digital engagement, market research, forecasting, and promotional strategy
  • Demonstrated ability to translate complex clinical/scientific data into differentiated commercial positioning
  • Experience working effectively across Medical Affairs, Clinical Development, Market Access, Regulatory, Sales, and executive leadership
  • Demonstrated understanding of the complex treatment, referral, reimbursement, and healthcare-provider ecosystem associated with specialty and cell therapies
  • Strong understanding of the unique challenges associated with launching innovative or highly specialized therapies
Kyverna Therapeutics logo

Kyverna Therapeutics

3.2 Glassdoor

Kyverna is a clinical-stage biopharmaceutical company focused on liberating autoimmune patients through the curative potential of cell therapy. Kyverna’s lead autologous CD19-targeting CAR T-cell therapy candidate, miv-cel (mivocabtagene autoleucel, KYV-101), has demonstrated the potential to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases.Kyverna is advancing its potentially first-in-class neuroimmunology franchise with its recently completed registrational trial in stiff person syndrome and an ongoing registrational trial for generalized myasthenia gravis. The Company is also harnessing other KYSA trials and investigator-initiated trials, including in multiple sclerosis and rheumatoid arthritis, to inform the next priority indications. Additionally, its next generation pipeline includes CAR T-cell therapies deploying novel innovations to improve patient access and experience.

Founded in 2018
Emeryville, California, USA
154 employees
47% recommend to a friend
100% CEO approval

Salaries

Posted range

$320K/yr – $350K/yr

Taken straight from the job posting.

See all Kyverna Therapeutics salaries

Marketing Team

Median Tenure
1.8 years
Marketing Roles Posted (Last 30 Days)
1

Funding

Total Funding
$295M
Last Raise
$100M
Post IPO Equity, 3 months ago

Funding History

  • Dec 2025
    Post IPO Equity • $100M
  • Nov 2025
    Post IPO Debt • $25M
  • Aug 2023
    Series B • $60M

Traffic Signals

Monthly Visitors
10.5K
Traffic Source Mix
Search
39.7%
Direct
43.6%
Referral
6.6%
Social
8.6%
Paid
1.3%

Headcount Trend

Current headcount: ~155

Recent News

Kyverna Therapeutics logo

Vice President, Marketing

Kyverna Therapeutics · USA · Remote